FDA grants breakthrough therapy designation to GSK’s GSK5764227 for relapsed or refractory extensive-stage small cell lung cancer

GSK5764227 was granted breakthrough therapy designation based on preliminary data from the ongoing ARTEMIS-001 Phase I trial, which showed promise for this novel treatment for patients with recurrent or refractory extensive-stage small cell lung cancer.